U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06939036) titled 'Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )' on April 15.
Brief Summary: This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing (SSTR2+) extensive-stage small cell lung cancer (ES-SCLC) and recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer Extensive Stage
Merkel Cell Carcinoma
Intervention:
DRUG: 225Ac-SSO110 + SoC
Dose Level ...